Biodexa Pharmaceuticals PLC Unsponsored ADR
BDRX Healthcare Biotechnology
Biodexa Pharmaceuticals PLC Unsponsored ADR’s revenue for fiscal 2023 (year ended December 2023) was $473,900.00, down 45.2% from fiscal 2022.
Follow BDRX
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) EV/Sales
As of 16 October 2026, Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) trades at a EV/Sales of −2.8×. Over the past ten years it has ranged from −14.5× (June 2021) to 0.0× (June 2020); the current reading is higher than 44% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | −4.7× | — |
| FY2022 | −1.7× | — |
| FY2021 | −12.3× | — |
| FY2020 | −14.5× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2023 | 469,234× | (59.16%) |
| Dec 2022 | 1,149,019× | (65.52%) |
| Jun 2022 | 3,332,714× | (66.42%) |
| Dec 2021 | 9,925,944× | (31.37%) |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LYRA Lyra Therapeutics, Inc. compare | −39.2× |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR | −2.8× |
| SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR compare | n/m |
| CDT CDT Equity Inc. compare | n/m |
| VINC Vincerx Pharma, Inc. compare | n/m |
| ATXI Avenue Therapeutics, Inc. compare | n/m |
| BTTX Better Therapeutics, Inc. compare | n/m |
| SEELQ Seelos Therapeutics, Inc. compare | 0.5× |
| EFTR eFFECTOR Therapeutics, Inc. compare | 3.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)